BXPHARMA
Pharma · Cat A · Mcap ৳4,357 cr৳148.200.00%Snapshot — the 20-second read
Mid-range for the year.
AI Verdict
Everything below, compressed into one honest read.
BXPHARMA screens constructive at 85/100. Working for it: trend, valuation, earnings quality, safety, timing. Against it: flow. Next catalyst: Q1 earnings (est.) (10-22).
3 buy · 3 neutral · 0 sell
Inside the Fair-Value Band — price roughly equals value.
A Verdict summarises this stock's own numbers on simulated data. It is not a rating and not investment advice.
Why It Is Moving Now
The move, explained in plain words.
Assembled from the simulated tape, the sector's move and the calendar. Not a language model, and not investment advice.
The chart
Price · Technical — KLineChart
Similarity Lab — who trades like BXPHARMA
Price Twins
Which stocks' charts genuinely look like this one — measured, not eyeballed.
Moves same-day — no lead-lag edge.
Spread +2.9σ — stretched; gaps like this historically close.
Moves same-day — no lead-lag edge.
Spread +0.3σ — inside its normal band.
Moves same-day — no lead-lag edge.
Spread +2.6σ — stretched; gaps like this historically close.
Diversifiers: POWERGRID (ρ 0.32) · TITASGAS (ρ 0.36) — pairing BXPHARMA with these adds genuine variety; holding twins adds almost none.
MASE 1.0 ≈ a typical one-day move of gap · TWIN = MASE < 2.4 with ρ > 0.55 · CLOSE = MASE < 3.4 · closes rebased to 100
Similarity is measured on simulated price history. A Twin is a statistical resemblance, not a relationship between the companies.
Compare
This stock beside another, on exactly the same measures.
| METRIC | BXPHARMA | RENATA |
|---|---|---|
| Price | ৳148.20 | ৳1,180.00 |
| Today | 0.00% | 0.00% |
| P/E | 11.6× | 28.0× |
| P/B | 1.61× | 4.40× |
| Yield | 2.4% | 1.2% |
| 30d momentum | +7% | -2% |
| Sponsor | 13.2% | 51.3% |
| Shield risk | 0/100 | 0/100 |
| Market cap | ৳4,357 cr | ৳19,824 cr |
Pharma vs Pharma. Simulated data; a comparison is not a preference.
Business · Ownership · Risk
Intraday Tape
Who is trading, and which way it is leaning.
Simulated trade data. Trade-size mix is this stock's normal profile, not today's tape; Pressure moves on every Tick.
Financials
Tap any metric for a plain-language explainer, in English and Bengali.
▼ cut from the year before · 4 of 8 years
5-Year Track Record
Is this a real, growing business? Five years tells the truth.
- Net margin
- 17.2%
- ● healthy
- Of every ৳100 sold, how much survives as profit.
- ROE
- 15.4%
- ● healthy
- How hard the company works your money. 14%+ is good here.
- Debt / Equity
- 1.04×
- ● weak
- Below 1× the debt load is manageable; above it, lenders own the upside.
- Current ratio
- 1.27×
- ● healthy
- 1.2×+ means it can pay its bills without stress.
Profit grew in 3 of the last 4 years · revenue trend +8%/yr · ROE 15%. That is a compounder profile — time works for you.
Simulated statements, generated from this stock's profile. Not filed accounts.
Report Digest
The annual report, in five lines.
- ▸Latest annual EPS ৳12.8 vs ৳11.9 prior year (+8%).
- ▸Book value ৳92.10/share; trades at 1.61× book (sector median ≈ 2.34×).
- ▸Dividend record: 8/8 years paid; current yield 2.4%.
- ▸Sponsors hold 13.2%, stable over the last quarter.
- ▸Shield risk 0/100 — no elevated manipulation signals at present.
Generated from simulated filings by a deterministic summariser, not a language model.
Market Depth
Who is queuing to buy versus sell right now.
| BID | QTY | ASK | QTY |
|---|---|---|---|
| 147.7 | 29.1k | 148.7 | 11.7k |
| 147.2 | 27.0k | 149.2 | 23.9k |
| 146.7 | 7.0k | 149.7 | 6.9k |
| 146.2 | 12.8k | 150.2 | 10.3k |
| 145.7 | 11.3k | 150.7 | 10.2k |
spread ৳0.5 · 0.34%
Simulated order book.
Manipulation Shield
How much the public data resembles a manipulated stock.
No elevated signals in the public data at present.
- Sponsor holding stable
- Volume within normal band
- No circuit events in 90 days
0 of 3 signals scored. Each is an observation about public data on simulated listings — not a finding of wrongdoing by any company or person.
Shareholding Shift
Are the founders and directors buying or leaving?
13.2%13.9%
Sponsor holding stable across quarters.
Ownership Structure
Who owns this company — and who moved last quarter.
- Sponsor / Director
- 13.2%
- -0.1pp
- Institution
- 19.6%
- -0.1pp
- Foreign
- 2.8%
- +0.3pp
- General public
- 64.5%
- -0.1pp
Sponsor holding is a Static Profile figure; the rest of the register is simulated like the rest of the tape.
Risk & Return Stats
How much pain this stock can inflict, in numbers.
- Beta vs DSEX
- 1.07
- Moves roughly with the market.
- Volatility (1Y)
- 11.0%
- How bumpy the ride is. This board's names cluster around 10–11% — higher means a rougher ride than peers.
- Max drawdown (1Y)
- -12%
- Worst peak-to-trough loss a holder actually lived through this year.
- Sharpe vs T-bill
- -0.80
- Extra return per unit of risk over the 10.15% T-bill. Above 0.3 earns its risk.
- P/E in 5y band
- 56%
- Band 7–15×: 0% = cheapest in 5y, 100% = richest.
Beta 1.07 with a 12% worst drawdown on this record. Over the period, the risk was not paid for — per unit of risk, the T-bill came out ahead.
Measured over a simulated year against a simulated index. These describe what has happened, not what will. Nothing here is investment advice.
Peer Radar · Pharma
Where this stock is strong, and where it is not.
Each axis is scaled to its own plausible range, so the shape shows where this stock is strong — never by how much. Simulated data.
Stock vs Index
Would you have beaten the market just holding this?
Beat the index in 3 of 5 windows. A mixed record against the market.
Returns are computed on a simulated price history against a simulated index. Past relative performance describes what happened, not what will. Nothing here is investment advice.
Watch Next
What is already on the calendar for this company.
- Q1 earnings (est.)10-22 · 61d
Simulated corporate calendar. Countdowns are measured from the session date, not from the wall clock.
Thesis Tripwires
What would have to happen for you to change your mind — watched for you.
Price falls below the Fair-Value Band (৳126.9)
The valuation case. Below the band the market is pricing in something the numbers here do not show.
A daily move beyond ±4%
The assumption that nothing is happening. A move this size is news, whether or not it has been published yet.
Shield risk reaches 60
The safety check. The score rises when the public data starts to look like a pump, whatever the price is doing.
Any sponsor filing
What is left of the insider-confidence case. Sponsors were already reducing last quarter.
A Tripwire is a condition you have decided matters, not a stop loss and not a price target. Alerts fire from the simulated tape and appear in Alerts.